Xaranetide (ARG-007) demonstrated significant neuroprotection and improved outcomes in moderate to severe stroke patients, with a clean safety profile and strong preclinical data in other neurological conditions. The company is advancing to late-stage trials and expanding into traumatic brain injury, with several regulatory and clinical milestones expected in 2026.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.